Cefpodoxime proxetil

Mostafa, Gamal A. E.; Al-Otaibi, Yazeed H.; Al-Badr, Abdullah A.

doi:10.1016/bs.podrm.2019.02.001

Cited by 4 publications

(3 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cefpodoxime is given as the pro-drug cefpodoxime proxetil and is commonly dosed between 100-200 mg twice-daily and has been found to be non-inferior to ciprofloxacin [117]. It is deesterified by the intestinal mucosa, with 50% bioavailability and around 80% of the absorbed dose excreted unchanged in the urine [220]. Peak urine concentration range from 49 mg/L (50 mg dose) to 196 mg/L (800 mg dose) [221].…”

Section: Oral Cephalosporinsmentioning

confidence: 99%

Antimicrobial pharmacokinetics and preclinicalin vitromodels to support optimized treatment approaches for uncomplicated lower urinary tract infections

Abbott

Roberts

Meletiadis

et al. 2020

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Introduction: Urinary tract infections (UTIs) are extremely common. Millions of people, particularly healthy women, are affected worldwide every year. One-in-two women will have a recurrence within 12-months of an initial UTI. Inadequate treatment risks worsening infection leading to acute pyelonephritis, bacteremia and sepsis. In an era of increasing antimicrobial resistance, it is critical to provide optimized antimicrobial treatment.Areas covered: Literature was searched using PubMed and Google Scholar (up to 06/2020), examining the etiology, diagnosis and oral antimicrobial therapy for uncomplicated UTIs, with emphasis on urinary antimicrobial pharmacokinetics (PK) and the application of dynamic in vitro models for the pharmacodynamic (PD) profiling of pathogen response.Expert opinion: The majority of antimicrobial agents included in international guidelines were developed decades ago without well-described dose-response relationships. Microbiology laboratories still apply standard diagnostic methodology that has essentially remained unchanged for decades. Furthermore, it is uncertain how relevant standard in vitro susceptibility is for predicting antimicrobial efficacy in urine. In order to optimize UTI treatments, clinicians must exploit the urine-specific PK of antimicrobial agents. Dynamic in vitro models are valuable tools to examine the PK/PD and urodynamic variables associated with UTIs, while informing uropathogen susceptibility reporting, optimized dosing schedules, clinical trials and treatment guidelines.

show abstract

Section: Oral Cephalosporinsmentioning

confidence: 99%

Antimicrobial pharmacokinetics and preclinicalin vitromodels to support optimized treatment approaches for uncomplicated lower urinary tract infections

Abbott

Roberts

Meletiadis

et al. 2020

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

show abstract

“…CFP is used in doses of 200-400 mg/day in respiratory and urinary tract infections, and 400-800 mg/day in skin infections. [11,12]. CFP is an orally administered and well-tolerated drug, however, it has only 50% oral bioavailability.…”

Section: Introductionmentioning

confidence: 99%

“…CFP is an orally administered and well-tolerated drug, however, it has only 50% oral bioavailability. In addition, CFP causes gastrointestinal side effects, commonly diarrhea, abdominal pain, nausea, vomiting, and rare adverse events including hemolytic anemia and agranulocytosis [12,13]. In order to overcome these obstacles and increase the efficacy of drugs, the development of nanoparticles is an innovative approach, in which researchers have shown great promise.…”

Section: Introductionmentioning

confidence: 99%

Antibacterial activity and cytocompatibility evaluation of cefpodoxime proxetil loaded eudragit rs 100 nanoparticles

AKARTAS,

ATES,

REIS

2024

jrp

View full text Add to dashboard Cite

The main purpose of this study is to design Cefpodoxime proxetil (CFP) loaded Eudragit RS 100 (ERS) nanoparticles to provide prolonged drug release, the enhanced oral efficacy of the drug at a lower oral dose. CFP-loaded nanoparticles are prepared by the single-emulsion solvent evaporation method with different drug:polymer ratios, F1 (CFP:ERS=1:1) and F2 (CFP:ERS=1:2). Physicochemical characterization, antibacterial activity, cytotoxicity profiles of nanoparticles are examined. F1 and F2 nanoparticles have a particle size of 236.70±3.05 and 258.87±11.32 nm, spherical shape, and a porous surface under SEM. The zeta potential values of F1 and F2 nanoparticles were 22.13±1.01 and 25.80±2.01 mV, and the encapsulation efficiencies were 34.37±3.71% and 55.78±3.52%, respectively. Since F2 nanoparticles have a smaller particle size, higher zeta potential, and encapsulation efficiency, this formulation was chosen as superior, and the subsequent experiments were continued with this formulation. The antibacterial activity of F2 nanoparticles against E.coli was found to be 2 times more effective than CFP. Cytotoxicity studies revealed that the cell viabilities in BEAS-2B and HepG2 cells were higher with the exposure to CFP nanoparticles (200 µg/ml) compared to CFP (100 µg/ml) alone. CFP nanoparticles have excellent efficacy and a cytocompatible profile in inhibiting the growth of bacteria compared to free CFP.

show abstract

An Investigation into the Solubility and Solution Thermodynamics of Cefpodoxime Proxetil in Different Solvents that Vary with Temperature

Bhola

Vaghani²,

Bhatt³

et al. 2022

Chemistry Africa

View full text Add to dashboard Cite

Cefpodoxime proxetil

Cited by 4 publications

References 100 publications

Antimicrobial pharmacokinetics and preclinicalin vitromodels to support optimized treatment approaches for uncomplicated lower urinary tract infections

Antimicrobial pharmacokinetics and preclinicalin vitromodels to support optimized treatment approaches for uncomplicated lower urinary tract infections

Antibacterial activity and cytocompatibility evaluation of cefpodoxime proxetil loaded eudragit rs 100 nanoparticles

An Investigation into the Solubility and Solution Thermodynamics of Cefpodoxime Proxetil in Different Solvents that Vary with Temperature

Contact Info

Product

Resources

About